



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

To,

Date: 14.08.2024

BSE Limited

P.J Towers, Dalal Street, Fort

Mumbai 400001

Dear Sirs,

Sub: Nil Statement on Deviation or Variation in utilization of Funds raised through Preferential allotment:

Pursuant to the provisions of Regulation 32 of the Securities and Exchange Board of India [“SEBI”] (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24 December, 2019 regarding “Format on Statement of Deviation or Variation for proceeds of public issue, rights issue, preferential issue, Qualified Institutions Placement (QIP) etc.”, we hereby confirm that there is no deviation or variation in the use of proceeds of the **Preferential allotment** from the objects stated in the Letter of Offer. A Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, is given in “**Annexure A**”.

Out of Rs. 10,99,02,562/- raised by the Company through the Preferential allotment, Rs. 10,99,02,562/- /- have been utilised for the objects as stated in the explanatory statement/Letter of offer during the quarter ended 30.06.2024.

Kindly take the same on record.

This intimation is also being uploaded on the Company’s website at www.vistapharmaceuticals.com

Thanking you

Yours faithfully

For Vista Pharmaceuticals Limited



Dhananjaya Alli

Executive Director

(DIN: 00610909)



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

Annexure-I

Nil Statement of Deviation/ Variation in utilization of Funds raised

Statement of Deviation / Variation in utilization of funds raised	
Name of listed entity	Vista Pharmaceuticals Limited
Mode of Fund Raising	Preferential Issue
Date of Raising Funds	28 th May, 2024 and 12.06.2024
Amount Raised	Rs. 10,99,02,562/-
Report filed for Quarter ended	30.06.2024
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a Deviation / Variation in use of fundraised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Dhananjay





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

Objects for which funds have been raised and where there has been a deviation, in the following Table						
Original Object	Modified Object, if any	Original Allocation	Modified allocation if any	Funds Utilized	Amount of Deviation/ Variation For the quarter according to applicable object	Remarks if any

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer etc.

Note: The entire proceeds raised by the Company through the Preferential Issue, during the quarter ended 30.06.2024, have been utilized for the objects as stated in the Letter of Offer/Explanatory statement.

Thanking you

For Vista Pharmaceuticals Limited



Dhananjaya Alli
Executive Director
(DIN: 00610909)